USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Mar 23, 2022 | Dec 2021 | $-0.22 | $-0.24 | $-0.34 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Mar 23, 2022 | Dec 2021 | $0.00 | $0.00 | $0.00 |
Corvus Pharmaceuticals's next earnings date is Wednesday, Mar 23, 2022 for the fiscal quarter ending Dec 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Mar 2022 | 2 | $-0.23 | $-0.31 | $-0.15 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 3 | $-0.85 | $-0.96 | $-0.64 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Mar 2022 | 2 / 0 | $-0.30 | $-0.30 | $-0.30 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 1 / 0 | $-0.90 | $-0.90 | $-0.90 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Mar 2022 | 2 | $0.00 | $0.00 | $0.00 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 3 | $0.00 | $0.00 | $0.00 |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 23, 2022 | Dec 2021 | $-0.22 | - | - |
| Nov 1, 2021 | Sep 2021 | $-0.24 | $-0.24 | -1.05% |
| Aug 2, 2021 | Jun 2021 | $-0.31 | $-0.28 | 10.40% |
| Apr 29, 2021 | Mar 2021 | $-0.32 | $-0.34 | -7.94% |
| Mar 25, 2021 | Dec 2020 | $-0.33 | $-0.34 | -4.29% |
| Oct 29, 2020 | Sep 2020 | $-0.22 | $-0.33 | -51.72% |
| Jul 30, 2020 | Jun 2020 | $-0.24 | $-0.36 | -51.58% |
| Apr 30, 2020 | Mar 2020 | $-0.41 | $-0.44 | -8.64% |
| Mar 5, 2020 | Dec 2019 | $-0.31 | $-0.38 | -22.58% |
| Oct 29, 2019 | Sep 2019 | $-0.43 | $-0.37 | 13.29% |
| Aug 1, 2019 | Jun 2019 | $-0.44 | $-0.44 | -0.76% |
| May 9, 2019 | Mar 2019 | $-0.48 | $-0.40 | 16.05% |
| Mar 7, 2019 | Dec 2018 | $-0.50 | $-0.36 | 28.00% |
| Nov 1, 2018 | Sep 2018 | $-0.49 | $-0.36 | 26.03% |
| Aug 2, 2018 | Jun 2018 | $-0.61 | $-0.40 | 34.16% |
| May 3, 2018 | Mar 2018 | $-0.77 | $-0.63 | 18.00% |
| Mar 1, 2018 | Dec 2017 | $-0.77 | $-0.58 | 24.58% |
| Nov 2, 2017 | Sep 2017 | $-0.84 | $-0.62 | 25.82% |
| Aug 3, 2017 | Jun 2017 | $-0.74 | $-0.73 | 1.12% |
| May 4, 2017 | Mar 2017 | $-0.77 | $-0.79 | -2.60% |
| Mar 10, 2017 | Dec 2016 | $-0.55 | $-0.55 | -0.73% |
| Nov 3, 2016 | Sep 2016 | $-0.45 | $-0.51 | -13.33% |
| Aug 4, 2016 | Jun 2016 | $-0.32 | $-0.43 | -36.38% |
| May 5, 2016 | Mar 2016 | $-6.09 | $-5.39 | 11.49% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 25, 2021 | Dec 2020 | $-1.46 | $-1.47 | - |
| Mar 5, 2020 | Dec 2019 | $-1.54 | $-1.59 | - |
| Mar 7, 2019 | Dec 2018 | $-1.83 | $-1.75 | - |
| Mar 1, 2018 | Dec 2017 | $-2.91 | $-2.72 | - |
| Mar 10, 2017 | Dec 2016 | - | $-6.88 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 23, 2022 | Dec 2021 | $0.00 | - | - |
| Nov 1, 2021 | Sep 2021 | $0.00 | $0.00 | - |
| Aug 2, 2021 | Jun 2021 | $0.00 | $0.00 | - |
| Apr 29, 2021 | Mar 2021 | $0.00 | $0.00 | - |
| Mar 25, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Oct 29, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Jul 30, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| Apr 30, 2020 | Mar 2020 | $0.00 | $0.00 | - |
| Mar 5, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Oct 29, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 1, 2019 | Jun 2019 | $0.00 | $0.00 | - |
| May 9, 2019 | Mar 2019 | $0.00 | $0.00 | - |
| Mar 7, 2019 | Dec 2018 | $0.00 | $0.00 | - |
| Nov 1, 2018 | Sep 2018 | $0.00 | $0.00 | - |
| Aug 2, 2018 | Jun 2018 | $0.00 | $0.00 | - |
| May 3, 2018 | Mar 2018 | $0.00 | $0.00 | - |
| Mar 1, 2018 | Dec 2017 | $0.00 | $0.00 | - |
| Nov 2, 2017 | Sep 2017 | $0.00 | $0.00 | - |
| Aug 3, 2017 | Jun 2017 | $0.00 | $0.00 | - |
| May 4, 2017 | Mar 2017 | - | $0.00 | - |
| Mar 10, 2017 | Dec 2016 | - | $0.00 | - |
| Nov 3, 2016 | Sep 2016 | - | $0.00 | - |
| Aug 4, 2016 | Jun 2016 | - | $0.00 | - |
| May 5, 2016 | Mar 2016 | - | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 25, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Mar 5, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Mar 7, 2019 | Dec 2018 | $0.00 | $0.00 | - |
| Mar 1, 2018 | Dec 2017 | $0.00 | $0.00 | - |
| Mar 10, 2017 | Dec 2016 | - | $0.00 | - |
CRVS's next earnings date is Wednesday, Mar 23, 2022 for the fiscal quarter ending Dec 31, 2021.
According to 3 analysts, the average EPS estimation for Corvus Pharmaceuticals's next quarterly earnings is $-0.22, with a low EPS estimation of $-0.27, and a high estimation of $-0.17.
Over the last 1 month, EPS estimates have seen 2 upward revisions and 0 downward. The EPS 1 month trend is $-0.22, the last 2 month trend is $-0.22, and the 3 month trend is $-0.22.
Based on 3 analysts, the average revenue estimation is $0.00, with a low revenue estimation of $0.00, and a high estimation of $0.00.
Corvus Pharmaceuticals's previous earnings date was Nov 1, 2021 for its fiscal quarter ended Sep 30, 2021.
CRVS's earnings per share (EPS) was $-0.24, missing the consensus analysts forecast of $-0.24 by -1.05%.
The EPS was higher than the previous fiscal quarter (Jun 2021) by -14.29%, and higher than the same period a year before (Sep 2020) by -27.27%.
Revenues were $0.00.
The company reported a net income of $-10.67M.Free cash flow for the quarter was $-8.43M , compared to $-12.65M last quarter and $-7.81M a year before.
CRVS ended the quarter with $3.88M in total debt, an increase of 117.77% compared to the previous quarter, and an increase of 53.13% compared to the same quarter a year before.
Corvus Pharmaceuticals's previous annual earnings date was Mar 25, 2021 for its fiscal year ended Dec 31, 2020.
CRVS's earnings per share (EPS) was $-1.47, missing the consensus analysts forecast of $-1.46 by 0.73% , and higher than the previous year's EPS (Dec 2019) by -7.50%.
Revenues were $0.00.
The company reported a net income of $-6.00M.
Corvus Pharmaceuticals reported a free cash flow of $-34.85M for its fiscal year, compared to $-37.35M a year ago.
The company ended the fiscal year with $2.31M in total debt, a decrease of -27.54% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
